When the Obvious Target Wasn't the Right One

The Client's Situation

The client had built something genuinely differentiated. Rather than sequencing a tumor's genome and inferring what it might do, their technology watched the cells behave. Working with live, patient-derived tumor cells, the platform measured dynamic changes in intracellular signaling molecules after ex vivo stimulation or inhibition — producing a functional signaling profile that reflected how the cells actually responded, and using that profile to predict disease status and likely therapeutic response.

They held a small number of patents covering this functional-signaling approach. And they had a suspicion that had been troubling them for some time: a particular competitor, active in the same precision-oncology space, appeared to be doing something very similar.

They came to us with a clear and confident brief — analyze the competitor's product and show that it infringes our portfolio.

The Complication

We took the brief seriously, which meant being willing to disprove it.

Our life-sciences analysts characterised the competitor's product in technical depth — its workflow, its readouts, the biological mechanism it relied upon — and mapped it, element by element, against the asserted claims of the client's patents. The comparison had to be exact, because in this field the difference between infringement and independence often lives in a single claim limitation.

And that is where the analysis landed. The competitor's product was addressing a similar clinical problem, but by a materially different process. Read honestly against the claim language, the competitor's workflow did not practise the client's claimed invention. It fell outside the claims.

This was not the answer the client had come for. It would have been easy — and commercially tempting — to strain the claim charts until they appeared to reach. We did not. We showed the client precisely where the two technologies converged and, more importantly, where they diverged, and explained why the divergence took the competitor's product outside the scope of the asserted claims.

"The client's immediate concern was resolved — the competitor was not, in fact, taking their invention. But it left a larger question open. If their most obvious suspect wasn't infringing, was anyone?"

The Turn

A single failed comparison answers one question narrowly: is this one company infringing? It says nothing about the field as a whole. So we proposed a different, broader piece of work — one that looked outward across the domain rather than at a single competitor.

We proposed target scouting: a systematic search of the precision-oncology landscape to identify any product or service that read on the client's claims, rather than testing a single pre-chosen suspect. The client agreed.

Working claim by claim across the portfolio, our team:

• Deconstructed the claims into their essential limitations, establishing precisely what any infringing product would have to do — measure a dynamic signaling response, in live patient-derived cells, following ex vivo perturbation, and use that functional profile predictively.
• Scanned the field for commercial products, diagnostic services and platforms whose technical descriptions matched that fingerprint — drawing on product literature, company technical disclosures, scientific publications, conference materials, and regulatory and clinical documentation.
• Filtered candidates against every limitation, discarding the many that resembled the client's approach superficially but diverged at a claim element — the same discipline that had, correctly, cleared the original competitor.
• For one patent in the portfolio in particular — the one whose claims mapped most cleanly onto commercially active technology — the scouting surfaced three strong mapping targets: three distinct products practising the claimed functional-signaling method.

The Escalation

Identifying a target is a hypothesis. Proving it is the work.

For each of the three targets, our analysts prepared detailed claim charts, mapping every element of the patent's claims to specific, evidenced features of that target's product — the biological workflow, the measurement of intracellular signaling dynamics, the ex vivo perturbation step, the predictive use of the resulting profile — with each mapping supported by the target's own public and technical documentation.

These were not directional sketches. They were the element-by-element Evidence of Use charts a patent owner needs to open a credible licensing conversation: specific enough to withstand a technically sophisticated counterparty, and honest about any element where the reading was strong versus where it depended on a reasonable interpretation.

The Outcome

The client used the three charted targets as the foundation of a licensing program for the portfolio — approaching the identified parties from a position built on evidence rather than assertion, with the technical mapping already in hand.

A portfolio that had been sitting defensively — held in case the original competitor ever needed to be confronted — became an active, revenue-oriented asset.